

FY2025 Financial Results

May 8, 2026

Forward-Looking Statements

Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable.

Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to:

Forward-looking statements:	This presentation contains forward-looking statements regarding the Company's future plans, strategies, and performance.
Current assumptions:	These statements are based on current expectations, assumptions, and information available to management at this time.
Risks and uncertainties:	Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
No guarantee of outcomes:	Forecasts, targets, and projections are not guarantees of future performance or achievement of stated goals.
Official guidance:	Official financial guidance should be referred to in accordance with relevant regulatory requirements and disclosures.
Product/market risks:	Risks include, but are not limited to, product development challenges, regulatory approvals, market acceptance, and competition.
Economic/industry risks:	Additional risks may arise from changes in economic conditions, currency fluctuations, and healthcare policy reforms.
No obligation to update:	The Company undertakes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Prevailing language:	In the event of any inconsistency between language versions, the original Japanese language version shall prevail.

Information about pharmaceutical products (including products currently in development) included in this document is not intended to constitute an advertisement of medical advice.

Today's Attendees

Toichi Takino

Representative Director,
President and Chief Operating Officer

Masaki Itoh

Corporate Executive Officer /
Chief Officer of Finance & Accounting Division

Tatsuya Okamoto

Corporate Officer /
Executive Vice President, Clinical Development

Hirokazu Kitada

Corporate Officer /
Executive Vice President, Sales and Marketing

FY2025 Financial Results and Future Vision (14:00-14:30)

Toichi Takino

Representative Director,
President and Chief Operating Officer

Pipeline Progress Status (14:30-14:45)

Tatsuya Okamoto

Corporate Officer /
Executive Vice President, Clinical Development


Q&A Session (14:45-15:15)

FY2025 Financial Results

Profit and Loss Recognition Period for Deciphera Pharmaceuticals, Inc.



Regarding the profit and loss recognition for Deciphera Pharmaceuticals, Inc., nine months were recorded in the same period last year, while twelve months have been recorded this year.



Main Points of the Financial Results

Achieved revenue and profit growth and record-highest earnings ever.

Full-Year Result (FY2025)

FY2025: Record-High Revenue and Profit with Strong Year-on-Year Growth

Revenue increased to 515.8 JPY bn (+5.9% YoY), driven by strong growth in overseas products, reaching a record high. Core operating profit increased to 137.1 JPY bn (+21.7% YoY), supported by improved cost efficiency. Core profit attributable to owners of the Company reached 103.5 JPY bn (+14.5% YoY), the highest level since the introduction of core indicators.*

Full-Year Forecast (FY2026)

FY2026 Outlook: Lower Revenue and Profit with Continued R&D Investment

Revenue is expected to be 455.0 JPY bn (-11.8% YoY), mainly due to the termination of the co-promotion agreement with AstraZeneca for Forxiga. The Company plans to continue investing in research and development at approximately 30% of net sales, in order to advance global clinical trials aimed at expanding its pipeline. Therefore, core operating profit is expected to be 124.0 JPY bn (-9.6% YoY).

Research & Development

- Tirabrutinib is under FDA review following NDA acceptance.
- Sapablursen has entered a global Phase 3 trial.
- Phase 2 data for ONO-4578 and ONO-2808 are expected to be presented at scientific meetings.
- Four new pipelines have advanced into Phase 1 trials.

FY2025 : Sales Revenue



Revenue

515.8 JPY bn

YoY +28.9 JPY bn
(+5.9%)



Goods and Products Sales

342.6 JPY bn

YoY +11.8 JPY bn (+3.6%)




Royalty and Others

173.2 JPY bn

YoY +17.1 JPY bn (+10.9%)

FY2025 : Sales Revenue (Breakdown)

Although sales of OPDIVO decreased due to intensified competitive environment, overall sales increased by 28.9 JPY bn year on year, mainly due to higher royalty revenue associated with OPDIVO and other products and revenue from Deciphera.



FY2025 : Sales Revenue by Product / Japan

JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Goods and products	330.8	<u>342.6</u>	11.8	3.6%	330.0
Royalty and others	156.1	<u>173.2</u>	17.1	10.9%	160.0

<u>Goods and Products (Japan)</u>	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
OPDIVO Intravenous Infusion	120.3	<u>114.3</u>	-6.0	-5.0%	120.0
FORXIGA Tablets	89.6	<u>88.2</u>	-1.4	-1.5%	80.0
ORENCIA for Subcutaneous Injection	26.6	<u>26.6</u>	-0.0	-0.0%	28.0
GLACTIV Tablets	18.3	<u>13.2</u>	-5.1	-27.9%	12.0
VELEXBRU Tablets	10.5	<u>11.9</u>	1.4	12.8%	11.0
ONGENTYS Tablets	7.6	<u>9.0</u>	1.3	17.3%	9.0
PARSABIV Intravenous Injection	8.4	<u>9.0</u>	0.6	6.6%	9.0
KYPROLIS for Intravenous Infusion	8.6	<u>7.5</u>	-1.1	-12.9%	9.0
BRAFTOVI Capsules	4.2	<u>5.6</u>	1.4	33.8%	—

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

• Sales revenue of domestic products is shown in a gross sales basis (shipment price), and sales revenue of overseas products is shown in a net sales basis.

FY2025 : Sales Revenue by Product / Overseas / Royalty



JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Goods and products	330.8	<u>342.6</u>	11.8	3.6%	330.0
Royalty and others	156.1	<u>173.2</u>	17.1	10.9%	160.0

Goods and Products (Overseas)	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
OPDIVO®	13.1	<u>14.2</u>	1.0	8.0%	13.5
QINLOCK®	25.5	<u>38.4</u>	12.9	50.6%	36.0
ROMVIMZA®	N/A	<u>8.3</u>	—	—	8.0

Royalty and others	FY2024	FY2025	YoY	
			Change	Change(%)
OPDIVO®	113.0	<u>122.3</u>	9.3	8.2%
KEYTRUDA®	26.4	<u>29.5</u>	3.0	11.4%

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

• Sales revenue of domestic products is shown in a gross sales basis (shipment price), and sales revenue of overseas products is shown in a net sales basis.

FY2025 : Core Operating Profit



Core Operating Profit
137.1 JPY bn

YoY +24.5 JPY bn
(+21.7%)



Revenue 515.8 JPY bn

YoY +28.9 JPY bn (+5.9%)



R&D Expense 145.1 JPY bn

YoY +1.8 JPY bn (+1.2%)




SG&A Expense 123.6 JPY bn

YoY +1.4 JPY bn (+1.1%)

FY2025 : Core Operating Profit (Breakdown)

While R&D and SG&A expenses have been recorded by Deciphera (the previous period accounted for nine months, and the current period includes twelve months), core operating profit increased by 24.5 JPY bn year on year to 137.1 JPY bn mainly due to an increase in sales revenue and promotion of cost efficiency.



FY2025 : Financial Overview (Core)

JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Cost of sales	106.9	<u>107.0</u>	0.2	0.2%	103.5
R&D expenses	143.3	<u>145.1</u>	1.8	1.2%	150.0
SG&A expenses	122.2	<u>123.6</u>	1.4	1.1%	120.0
Core operating profit	112.7	<u>137.1</u>	24.5	21.7%	114.0
Core profit before tax	113.9	<u>138.3</u>	24.4	21.4%	114.0
Core profit for the year (attributable to owners of the Company)	90.4	<u>103.5</u>	13.1	14.5%	91.0

YoY Breakdown

Cost of sales +0.2 JPY bn (+0.2%)

COGS ratio : 20.8%

R&D expenses +1.8 JPY bn (+1.2%)

R&D ratio : 28.1%

Main reason

- Increase in R&D expenses from Deciphera (previous year : nine months, current year: twelve months)

SG&A expenses +1.4 JPY bn (+1.1%)

SG&A ratio : 24.0%

Main reason

- Increase in SG&A expenses from Deciphera (previous year : nine months, current year : twelve months)

Core operating profit ratio : 26.6%

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

(Ref) FY2025 : Financial Overview (Full Basis)

JPY bn	FY2024	FY2025	YoY		FY2025 Forecast*
			Change	Change(%)	
Revenue	486.9	<u>515.8</u>	28.9	5.9%	490.0
Cost of sales	147.9	<u>141.7</u>	-6.2	-4.2%	135.0
R&D expenses	149.9	<u>147.0</u>	-2.8	-1.9%	150.0
SG&A expenses	125.7	<u>123.7</u>	-2.0	-1.6%	120.0
Operating profit	59.7	<u>92.2</u>	32.5	54.4%	85.0
Profit before tax	59.3	<u>92.7</u>	33.3	56.2%	85.0
Profit for the year (attributable to owners of the Company)	50.0	<u>69.8</u>	19.7	39.4%	67.0

YoY Breakdown

Cost of sales -6.2JPY bn (-4.2%)

COGS ratio : 27.5%

Main reason

- Absence of the sales milestone payment recorded in the previous fiscal year.

R&D expenses -2.8 JPY bn (-1.9%)

R&D ratio : 28.5%

Main reasons

- Increase in R&D expenses from Deciphera
- Absence of impairment loss related to development compounds recorded in the previous fiscal year

SG&A expenses -2.0 JPY bn (-1.6%)

SG&A ratio : 24.0%

Main reasons

- Increase in SG&A expenses from Deciphera
- Absence of expenses associated with the acquisition of Deciphera

Operating profit ratio : 17.9%

* The consolidated financial forecast for the fiscal year ended March 2026, announced on October 30, 2025, is provided.

(Ref) FY2025 : Reconciliation from Full to Core Basis

JPY bn	IFRS (Full) basis	Adjustment				Core basis
		Amortization	Impairment loss	Others	Total	
Revenue	515.8				—	515.8
Cost of sales	141.7	-25.6		-9.1	-34.7	107.0
Gross profit	374.1	+25.6	—	+9.1	+34.7	408.7
R&D expenses	147.0		-1.9		-1.9	145.1
SG&A expenses	123.7			-0.1	-0.1	123.6
Other income /expenses (- Exp)	-11.1		+0.2	+8.0	+8.2	-2.9
Operating profit	92.2	+25.6	+2.1	+17.2	+44.9	137.1
Operating profit ratio	17.9%				—	26.6%
Finance income / Finance cost (- Exp)	0.4			+0.7	+0.7	1.1
Profit before tax	92.7	+25.6	+2.1	+17.9	+45.6	138.3
Income tax expense	22.7	+6.5	+0.6	+4.8	+11.9	34.6
Profit for the year	69.8	+19.2	+1.5	+13.1	+33.7	103.5

Breakdown

Cost of sales

Main reasons

- Amortization expenses related to intangible assets acquired through acquisitions or in-licensing
- Amortization expenses related to inventories from *PPA

R&D expenses

Main reason

- Amortization expenses related to development compounds

SG&A expenses and Other income&expense


Main reasons

- Loss on retirement benefit plan amendments
- Loss on product recall related to OPDIVO
- Loss on the termination of the co-promotion agreement for FORXIGA Tablets

*PPA : Purchase Price Allocation


Balance sheet (Consolidated)

Structural transformation toward growth driven by proactive strategic investments



Capital Allocation (FY2022-2026)

■ Planned as of Apr 2022
 ■ Assumption for FY2025-2026
 ■ Result of FY2022-2024



FY2026 Financial Forecasts

FY2026 : Financial Forecast



Revenue
455.0 JPY bn

YoY -60.8 JPY bn
(-11.8%)



Goods and Products Sales
270.0 JPY bn

YoY -72.6 JPY bn (-21.2%)



Royalty and Others
185.0 JPY bn

YoY +11.8 JPY bn (+6.8%)

FY2026 : Financial Forecast (Sales by Product)

JPY bn


Goods and Products (Japan)	FY2025	FY2026 Forecast	YoY	
			Change	Change (%)
OPDIVO Intravenous Infusion	114.3	<u>120.0</u>	5.7	5.0%
ORENCIA for Subcutaneous Injection	26.6	<u>19.0</u>	-7.6	-28.6%
VELEXBRU Tablets	11.9	<u>12.0</u>	0.1	0.9%
PARSABIV Intravenous Injection	9.0	<u>10.0</u>	1.0	11.2%
ONGENTYS Tablets	9.0	<u>10.0</u>	1.0	11.5%
GLACTIV Tablets	13.2	<u>9.5</u>	-3.7	-28.1%
BRAFTOVI Capsules	5.6	<u>8.5</u>	2.9	51.5%
KYPROLIS for Intravenous Infusion	7.5	<u>7.0</u>	-0.5	-6.6%

Goods and Product (Overseas)	FY2025	FY2026 Forecast	YoY	
			Change	Change (%)
OPDIVO®	14.2	<u>13.0</u>	-1.2	-8.2%
QINLOCK®	38.4	<u>43.0</u>	4.6	12.1%
ROMVIMZA	8.3	<u>19.0</u>	10.7	129.4%

* Sales revenue of domestic products is shown in a gross sales basis (shipment price).

* Sales revenue of overseas products is shown in a net sales basis.

OPDIVO Sales Trend by Each Cancer




Progress Status of Key Indications (Apr. 2025 – Mar. 2026)

- GC : Progressed as per revised plan despite impact of competing products
- NSCLC : New prescription share in the PD-L1 negative segment is growing, but has not reached the plan; further activities are being strengthened to further expansion
- ESC : Although new competing products have entered the market, new prescription share increased and progress is on track
- HC / CRC : New prescription share remains steady

ROMVIMZA – Commercial Progress


Key Highlights

- ◆ Regulatory approvals obtained in the U.S. (FDA, February 2025) and Europe (EMA, September 2025)
- ◆ Market penetration progressing at a pace exceeding initial expectations
- ◆ In the TGCT market, a rare-disease area, increasing disease awareness and timely initiation of appropriate treatment are critical




ROMVIMZA Growth Opportunities in the TGCT Market

- ◆ In the TGCT market, a rare-disease area, increasing disease awareness and timely initiation of appropriate treatment are critical




Awareness-Building Initiatives in Orthopedics

Symposium





Website



Expansion and Acceleration of Global Business

Expand the share of global sales excluding Japan



FY2026 : Financial Forecast (Core Operating Profit)



Core Operating Profit
124.0 JPY bn

YoY -13.1 JPY bn
(-9.6%)



Revenue 455.0 JPY bn

YoY -60.8 JPY bn (-11.8%)



R&D Expense 143.0 JPY bn

YoY -2.1 JPY bn (-1.5%)



SG&A Expense 101.0 JPY bn

YoY -22.6 JPY bn (-18.3%)

(Ref) FY2026 : Financial Forecast (Core/Compared to the Previous Year)



JPY bn	FY2025 Actual	FY2026 Forecast	Change	Change (%)
Revenue	515.8	<u>455.0</u>	-60.8	-11.8%
Cost of sales	107.0	<u>84.0</u>	-23.0	-21.5%
R&D expenses	145.1	<u>143.0</u>	-2.1	-1.5%
SG&A expenses	123.6	<u>101.0</u>	-22.6	-18.3%
Core operating profit	137.1	<u>124.0</u>	-13.1	-9.6%
Core profit before tax	138.3	<u>124.0</u>	-14.3	-10.3%
Income tax expense	34.6	<u>31.0</u>	-3.6	-10.5%
Core profit for the year (attributable to owners of the Company)	103.5	<u>93.0</u>	-10.5	-10.1%

Breakdown

Cost of sales -23.0 JPY bn (-21.5%)

COGS ratio : 18.5%

Main reason

- Decrease in sales related to FORXIGA tablets due to the termination of the co-promotion agreement

R&D expenses -2.1 JPY bn (-1.5%)

R&D ratio: 31.4%

Main reasons

- A reclassification of certain expenses previously recorded as R&D expenses to SG&A expenses
- Increase in global clinical trial costs

SG&A expenses -22.6 JPY bn (-18.3%)

SG&A ratio : 22.2%

Main reason


- The termination of co-promotion agreement for FORXIGA Tablets

Core operating profit ratio : 27.3%

* The exchange rate assumed in the financial forecast is ¥155 per US dollar.

Core Operating Profit and Other Expense Trends

In FY2026, continue R&D investment, while anticipating reductions in SG&A expenses and cost of sales.



FY2026 : Financial Forecast (Full / Compared to the Previous Year)



JPY bn	FY2025 Actual	FY2026 Forecast	Change	Change (%)
Revenue	515.8	<u>455.0</u>	-60.8	-11.8%
Cost of sales	141.7	<u>114.0</u>	-27.7	-19.6%
R&D expenses	147.0	<u>143.0</u>	-4.0	-2.7%
SG&A expenses	123.7	<u>101.0</u>	-22.7	-18.3%
Operating profit	92.2	<u>94.0</u>	1.8	1.9%
Profit before tax	92.7	<u>94.0</u>	1.3	1.5%
Income tax expense	22.7	<u>23.0</u>	0.3	1.1%
Profit for the year (attributable to owners of the Company)	69.8	<u>71.0</u>	1.2	1.8%

Breakdown

Cost of sales -27.7 JPY bn (-19.6%)

COGS ratio : 25.1%

Main reason

- Decrease in sales related to FORXIGA tablets due to the termination of the co-promotion agreement

R&D expenses -4.0 JPY bn (-2.7%)

R&D ratio: 31.4%

Main reasons

- A reclassification of certain expenses previously recorded as R&D expenses to SG&A expenses
- Increase in global clinical trial costs

SG&A expenses -22.7 JPY bn (-18.3%)

SG&A ratio : 22.2%

Main reason

- The termination of co-promotion agreement for FORXIGA Tablets


Operating profit ratio : 20.7%

* The exchange rate assumed in the financial forecast is ¥155 per US dollar.

The sensitivity to exchange rates is assumed to be an increase of ¥1.5 billion in revenue and an increase of ¥0.5 billion in operating profit for every ¥1 depreciation of the yen.

Profit Distribution (Dividend)

Dividends are to be paid out in accordance with a progressive policy of maintaining or increasing the annual dividend each year, with a target payout ratio of 40%, taking into account the performance of each fiscal year and various indices.




Dividend payout ratio (consolidated)

Key Development Pipeline Milestones

As of May 8, 2026

- Initiation of three global Phase 3 and data readouts from seven POC studies in FY2026
- In the priority areas of oncology, immunology & inflammation, and neurology, four new pipelines have initiated phase 1 study.



Tirabrutinib Development Status in the United States

Tirabrutinib is an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor that is currently under review by the U.S. FDA for the treatment of relapsed or refractory primary central nervous system lymphoma (R/R PCNSL).


- Positive results from Phase 2 PROSPECT study demonstrated overall response rate of 67%, complete response rate of 44%
- PDUFA date set for 12/18/2026
- Preparing for U.S. commercialization
- Recruiting patients for Global Phase 3 confirmatory study



Source: PCNSL Disease Awareness Website
<https://www.navigatingpcnsl.com/>

Prospect for the Future

Growth Drivers



Pipeline	Peak Sales (JPY bn)
Global	
QINLOCK (GIST)	50 – 70
ROMVIMZA (TGCT)	50 – 70
Tirabrutinib (PCNSL)	20 – 30
Sapablursen (PV)	50 – 100
ONO-4578 (GC)	100 -
ONO-2808 (MSA)	100 -
Japan*	
Povetacicept	50 -
Cenobamate	
Gel-One®	

*Total estimated peak sales, including products other than the three listed.

Japan Sales

※Diagram does not represent actual sales of each product

As of May 8, 2026

Development Pipeline Progress Status

Launch Projections - POC Pipeline-

As of May 8, 2026

■ Approved ■ Filed and preparing for filing

	FY2025	FY2026	FY2027	FY2028	FY2029 -	
US 		ONO-4059 (VELEXBRU) PCNSL	QINLOCK GIST 2L		ONO-0530 sapablursen PV	ONO-4578 GC 1L ONO-2808 MSA
EU 	ROMVIMZA TGCT		QINLOCK GIST 2L		ONO-0530 sapablursen PV	ONO-4578 GC 1L ONO-2808 MSA
JP 	OPDIVO HCC 1L OPDIVO MSI-H CRC 1L BRAFTOVI CRC 1L FOLFOX	ONO-2017 cenobamate Partial-onset seizures QINLOCK GIST 4L	OPDIVO HCC Adjuvant	ripretinib (QINLOCK) GIST 2L VELEXBRU Pemphigus 2L ONO-2017 cenobamate Primary generalized tonic-clonic seizures ONO-8531 povetacicept IgAN	ONO-5532 Gel-One Osteoarthritis ONO-2017 cenobamate Partial-onset seizures pediatric vimseltinib (ROMVIMZA) TGCT OPDIVO sc	ONO-0530 sapablursen PV ONO-8531 povetacicept pMN ONO-4578 GC 1L ONO-2808 MSA

PCNSL: Primary Central Nervous System Lymphoma, GIST: Gastrointestinal Stromal Tumor, PV: Polycythemia Vera, GC: Gastric Cancer, MSA: Multiple System Atrophy, TGCT: Tenosynovial Giant Cell Tumor, HCC: Hepatocellular Carcinoma, CRC: Colorectal Cancer, IgAN: IgA Nephropathy, pMN: Primary Membranous Nephropathy

Development pipeline (Oncology) ①



As of May 8, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	PII	PIII	F	A	Status	Area	ID
BRAFTOVI Capsule (encorafenib) BRAF inhibitor	Colorectal cancer 1L BRAF-mutation (with cetuximab and chemo (FOLFOX))							2025.11 JP : Approval 2026.1 KR : Approval	JP, US, EU, KR, TW and others* ¹	NCT04607421
ONO-4059 (tirabrutinib) BTK inhibitor	Primary central nervous system lymphoma (PCNSL) 1L, ≥2L							2026.2 US : Filed (Part A)	US	NCT04947319
	Primary central nervous system lymphoma (PCNSL) ≥2L							FY2027 Primary Completion	US	NCT07104032
QINLOCK DCC-2618 (ripretinib) KIT inhibitor	Gastrointestinal Stromal Tumor (GIST) 2L KIT Exon 11+17/18							FY2027 Primary Completion	US, EU, KR, TW and others	NCT05734105
	Gastrointestinal Stromal Tumor (GIST) 4L							FY2026 Primary Completion	JP	Under registration
ONO-0530 (sapablursen) Antisense oligonucleotide targeting TMPRSS6	Polycythemia Vera (PV)							FY2028 Primary Completion	JP, US, EU, KR, TW and others	NCT07429266
ONO-4578 PG receptor (EP4) antagonist	Gastric cancer*							FY2025 Primary Completion (Actual)	JP, KR, TW	NCT06256328
	Colorectal cancer*							FY2027 Primary Completion	JP, US, EU and others	NCT06948448
	Non-small cell lung cancer*							FY2026 Primary Completion	JP	NCT06542731
ONO-4482 (relatlimab) Anti-LAG-3 antibody	Melanoma*							FY2024 Primary Completion (Actual)	JP, US, EU and others	NCT01968109
ONO-7427 Anti-CCR8 antibody	Solid tumor*							FY2028 Primary Completion	JP, US, EU and others* ²	NCT04895709
DCC-3116 (inlexisertib) ULK inhibitor	Advanced Malignancies (with ripretinib)							FY2026 Primary Completion	US, EU	NCT05957367

MOA : Mode of Action
* : Combination with OPDIVO

*¹ : Development rights countries: JP, KR, *² : Development right country: JP
Estimated study completion date shown in jRCT or ClinicalTrials.gov

F : Filed, A : Approval
EU : European countries

※Red: Update after announcement of FY 2024 financial result in May 2025
※Red: Update after FY2025 Q3 in February

Development pipeline (Oncology) ②



As of May 8, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	PII	PIII	F	A	Status	Area	ID
DCC-3009 Pan-KIT inhibitor	Gastrointestinal Stromal Tumor (GIST)							FY2028 Primary Completion	US	NCT06630234
ONO-4685 (besufetamig) PD-1 x CD3 bispecific antibody	T-cell lymphoma							FY2027 Primary Completion	US	NCT05079282
								FY2028 Primary Completion	JP	NCT06547528
ONO-8250 iPSC-derived HER2 CAR T-cell therapy	HER2-expressing Solid tumor							FY2029 Primary Completion	US	NCT06241456
ONO-7428 Anti-ONCOKINE-1 antibody	Solid tumor							FY2029 Primary Completion	JP	NCT06816108
DCC-2812 GCN2 Activator	Renal Cell Carcinoma, Urothelial Cancer, Castration-Resistant Prostate Cancer							FY2028 Primary Completion	US	NCT06966024
ONO-7429 Anti-L1CAM ADC	Solid tumor							FY2028 Primary Completion	JP	Under registration

MOA : Mode of Action

* : Combination with OPDIVO
Estimated study completion date shown in jRCT or ClinicalTrials.gov

F : Filed, A : Approval

※Red: Update after announcement of FY 2024 financial result in May 2025
※Red: Update after FY2025 Q3 in February

Development pipeline (Non-oncology) ①



As of May 8, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	PII	PIII	F	A	Status	Area	ID
ROMVIMZA DCC-3014 (vimseltinib) CSF-1R inhibitor	Tenosynovial Giant Cell Tumor (TGCT)							FY2024 US : Approval FY2025 EU : Approval	US, EU and others	NCT05059262
	chronic Graft Versus Host Disease (cGVHD)							FY2029 Primary Completion	US	NCT06619561
ONO-2017(cenobamate) Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABA _A ion channel	Partial-onset seizures							FY2025 JP : Filed	JP, KR and others*1	NCT04557085
	Partial-onset seizures (pediatric)							FY2028 Primary Completion	JP	Under registration
	Primary generalized tonic-clonic seizures							FY2026 Primary Completion	JP	NCT06579573
VELEXBRU Tablet (ONO-4059 : tirabrutinib) BTK inhibitor	Pemphigus							FY2027 Primary Completion	JP	NCT06696716
ONO-8531 (povetacicept) BAFF/APRIL dual antagonist	IgA Nephropathy							FY2027 Primary Completion	JP, US, EU, KR, TW and others*2	NCT06564142
	Primary Membranous Nephropathy							FY2028 Primary Completion	US, EU, KR and others*2	NCT07204275
ONO-5532 (Gel-One) Cross-linked hyaluronate	Knee osteoarthritis							FY2027 Completion	JP	jRCT2031240621
	Hip osteoarthritis							FY2027 Completion	JP	jRCT2061240110
ONO-2808 S1P5 receptor agonist	Multiple System Atrophy (MSA)							FY2025 Primary Completion (Actual)	JP, US	NCT05923866

*1 : Development right country: JP, *2 : Development rights countries: JP, KR, *3 : P II b/III
MOA : Mode of Action Estimated study completion date shown in jRCT or ClinicalTrials.gov

F : Filed, A : Approval
EU : European countries

※Red: Update after announcement of FY 2024 financial result in May 2025
※Red: Update after FY2025 Q3 in February

Development pipeline (Non-oncology) ②



As of May 8, 2026

Code (Generic name) MOA, Modality	Target Indication	PI	PI/II	PII	PIII	F	A	Status	Area	ID
ONO-1110 Endocannabinoid regulation	Postherpetic Neuralgia							FY2026 Primary Completion	JP	NCT06708416
	Fibromyalgia							FY2026 Primary Completion	JP	NCT06752590
	Hunner Type Interstitial Cystitis							FY2026 Primary Completion	JP	NCT06752603
	Major Depressive Disorder							FY2026 Primary Completion	JP	NCT06792136
	Social Anxiety Disorder							FY2026 Primary Completion	JP	NCT06805565
ONO-2020 Epigenetic Regulation	Alzheimer's Disease							FY2026 Primary Completion	JP, US	NCT06881836
	Agitation Associated with Dementia Due to Alzheimer's Disease							FY2026 Primary Completion	JP	NCT06803823
ONO-4685 (besufetamig) PD-1 x CD3 bispecific antibody	Autoimmune disease							FY2024 Completion	JP	jRCT2071220081
								FY2024 Primary Completion (Actual)	EU	NCT05332704
ONO-4915 PD-1 x CD19 bispecific antibody	Autoimmune disease							FY2026 Completion	JP	jRCT2071240056
ONO-2416	Psychiatric disorders							FY2027 Completion	JP	jRCT2071250147
ONO-3310	Kidney disease							FY2027 Completion	JP	Under registration
ONO-6414	Autoimmune disease							FY2027 Primary Completion	US	Under registration

MOA : Mode of Action

Estimated study completion date shown in jRCT or ClinicalTrials.gov
Shaded boxes indicate studies on healthy volunteers.

F : Filed, A : Approval
EU : European countries

※Red: Update after announcement of FY 2024 financial result in May 2025
※Red: Update after FY2025 Q3 in February

ONO-2808

7th World Parkinson Congress

Title : Safety, Tolerability, and Preliminary Efficacy of ONO-2808,
a Sphingosine-1-Phosphate Receptor 5 Agonist, in Multiple System Atrophy

Abstract No. : LBP37.09, Poster session

Time : Wednesday, May 27, 2026 11:30 am – 1:30pm (MST)

ONO-4578

ASCO 2026 (American Society of Clinical Oncology)

Title : ONO-4578 combined with nivolumab and chemotherapy as first-line treatment for patients with
HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: a
randomized, double-blind, phase 2 trial (ONO-4578-08)

Abstract No. : 4007, Oral presentation

Time : Monday, June 1, 2026, 9:45 am to 12:45 pm (CT)

Presenter : Sung Hee Lim, Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, Republic of Korea

Appendix

Development status of OPDIVO



As of May 8, 2026

- Approval or filed/awaiting approval in the past year
- Ongoing key clinical trials for approval

Target disease	Treatment Line	Treatment	Phase				
			Japan	Korea	Taiwan	US	EU
Non-small cell lung cancer	Neo-adjuvant・Adjuvant	with Chemo	III	III	III	Approved	Approved
Colorectal cancer	MSI-H / dMMR (1st)	with Ipi	Approved	Approved	Approved	Approved	Approved
Hepatocellular carcinoma	Adjuvant	Monotherapy	III	III	III	III	III
	1st	with Ipi	Approved	Approved	Approved	Approved	Approved
Rhabdoid tumor	2nd	Monotherapy	II	—	—	—	—
Richter transformation	2nd	Monotherapy	II	—	—	—	—
Solid tumor	—	ONO-4538HSC (Combination with vorhyaluronidase alfa)	I	—	—	Approved	Approved

※Red: Update after announcement of FY 2024 financial result in May 2025
 ※Red: Update after FY2025 Q3 in February

OPDIVO Approval Track Record(1)



As of May 8, 2026

Target disease	Treatment Line	Treatment	Phase				
			Japan	Korea	Taiwan	US	EU
Melanoma	Adjuvant•1st•2nd	Monotherapy, with Ipi (1st only)	Approved	Approved	Approved	Approved	Approved
	1st	Combination drug [†] (relatlimab)	–	–	–	Approved	Approved
Non-small cell lung cancer	Neo-adjuvant	with Chemo	Approved	Approved	Approved	Approved	Approved
	1st	with Ipi	Approved	Approved	Approved	Approved	–
		with Ipi / Chemo	Approved	Approved	Approved	Approved	Approved
		with Chemo	Approved	–	–	–	–
		with Chemo (NSQ)	Revision of labeling	Approved	Approved	–	–
	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
Hodgkin's lymphoma	Relapsed / Refractory	Monotherapy	Approved	Approved	Approved	Approved	Approved
Head and neck cancer	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
Malignant pleural mesothelioma	1st	with Ipi	Approved	Approved	Approved	Approved	Approved
	2nd	Monotherapy	Approved	–	–	–	–
Malignant mesothelioma (Excluding Pleura)	1st	Monotherapy	Approved	–	–	–	–

[†]Combination drug (Relatlimab) : ONO-7121(Opdivo+Relatlimab (ONO-4482))

OPDIVO Approval Track Record(2)



As of May 8, 2026

Target disease	Treatment Line	Treatment	Phase				
			Japan	Korea	Taiwan	US	EU
Gastric cancer	1st	with Chemo	Approved	Approved	Approved	Approved	Approved
	3rd	Monotherapy	Approved	Approved	Approved	–	–
Esophageal cancer	Adjuvant	Monotherapy	Approved	Approved	Approved	Approved	Approved
	1st	with Ipi, with Chemo	Approved	Approved	Approved	Approved	Approved
	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
Colorectal cancer	MSI-H / dMMR (3rd)	Monotherapy	Approved	–	Approved	Approved	–
		with Ipi	Approved	Approved	Approved	Approved	Approved★★
Hepatocellular carcinoma	2nd	with Ipi	–	–	Approved	Approved	–

★★2nd Line

OPDIVO Approval Track Record(3)



As of May 8, 2026

Target disease	Treatment Line	Treatment	Phase				
			Japan	Korea	Taiwan	US	EU
Renal cell carcinoma	1st	with Ipi	Approved	Approved	Approved	Approved	Approved
		with TKI	Approved	Approved	Approved	Approved	Approved
	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
Urothelial cancer / Bladder cancer	Adjuvant	Monotherapy	Approved	Approved	Approved	Approved	Approved
	1st	with Chemo	Approved	Approved	Approved	Approved	Approved
	2nd	Monotherapy	–	Approved	Approved	Approved	Approved
Cancer of unknown primary	1st	Monotherapy	Approved	–	–	–	–
Epithelial skin malignancies	1st	Monotherapy	Approved	–	–	–	–
Flat dose	240 mg (every 2 weeks)		Approved	Approved	Approved	Approved	Approved
	360 mg (every 3 weeks)		Approved	Approved	Approved	Approved	Approved
	480 mg (every 4 weeks)		Approved	Approved	Approved	Approved	Approved

Key milestones in FY2025 Q4 (FY ending March 2026)



As of May 8, 2026

(Development pipeline)

	Product/ Code(Generic name)	Target indication/Study name	Progress
Product to be approved	OPDIVO	MSI-high Colorectal cancer(1st with Ipi) / CheckMate-8HW	Approved in TW (Jan.2026) Approved in KR (Feb.2026)
	BRAFTOVI / ONO-7702 (encorafenib)	Colorectal cancer 1L BRAF-mutation (with Cetuximab and chemo (FOLFOX))	Approved in KR (Jan.2026)
	ONO-4059 (tirabrutinib)	Primary central nervous system lymphoma (PCNSL) ≥2L	Filed in US (Dec.2025) Filing accepted in US (Feb.2026)
	QINLOCK / DCC-2618 (ripretinib)	Gastrointestinal Stromal Tumor (GIST) 4L	Filed in JP (Mar.2026)
P3	ONO-0530 (sapablursen)	Polycythemia Vera (PV)	Started in JP, US, EU, KR, TW (Feb.2026)
	ONO-2017 (cenobamate)	Partial-onset seizures (pediatric)	Started in JP (Feb.2026)
	OPDIVO	Bladder cancer Neo-adjuvant• Adjuvant (with Chemo) / ONO-4538-86	Discontinued (Apr.2026)
P2b / P3	ONO-8531 (povetacicept)	Primary Membranous Nephropathy (pMN)	Started by Vertex in US, EU, KR (Sep.2025)
P1	ONO-7429	Solid Tumor	Started in JP (Mar.2026)
	ONO-2416	Psychiatric disorders	Started in JP (Feb.2026)
	ONO-3310	Kidney disease	Started in JP (Mar.2026)
	ONO-6414	Autoimmune disease	Started in US (Apr.2026)
	ONO-4578	Hormone receptor-positive, HER2-negative breast cancer	Discontinued (Mar.2026)
	ONO-7913 (magrolimab)	Colorectal cancer, Pancreatic cancer (with OPDIVO)	Discontinued (Apr.2026)

Key milestones in FY2025 Q4 (FY ending March 2026)



As of May 8, 2026

(Drug discovery partnerships & Research collaborations / Licensing & Co-promotion)

Title	Progress
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology (Mar.2026-)	Started
Ono Enters into a Drug Discovery Collaboration Agreement with EME Aiming at the Generation of Novel VHH Antibody Drugs (Feb.2024-)	Discontinued



ONO PHARMA

Dedicated to the Fight against Disease and Pain